BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12704462)

  • 1. [Adjuvant interferon treatment of melanoma].
    Török L
    Magy Onkol; 2003; 47(1):105-7. PubMed ID: 12704462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How melanoma is treated in real life.
    Dummer R; Schadendorf D
    Arch Dermatol; 2008 May; 144(5):664-5. PubMed ID: 18490596
    [No Abstract]   [Full Text] [Related]  

  • 5. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant therapy for malignant melanoma.
    Stoutenburg JP; Schrope B; Kaufman HL
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant interferon in melanoma - a resurrection?
    Middleton MR; Thatcher N
    Br J Cancer; 2001 May; 84(9):1141-2. PubMed ID: 11336461
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant high-dose interferon therapy for high-risk melanoma.
    Ready N; Weinstock MA
    Arch Dermatol; 2003 Dec; 139(12):1635-7. PubMed ID: 14676083
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
    Wcisło G; Szczylik C
    Pol Merkur Lekarski; 2003 Jul; 15(85):5-8. PubMed ID: 14593950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adjuvant interferon therapy in malignant melanoma].
    Mohr P
    J Dtsch Dermatol Ges; 2007 Jun; 5(6):543-5. PubMed ID: 17537052
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
    Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
    Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninterferon-based adjuvant therapy for high-risk melanoma.
    Spitler LE
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):547-62. PubMed ID: 12382523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
    Kimyai-Asadi A; Usman A
    J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment of malignant melanoma: where are we?
    Ascierto PA; Scala S; Ottaiano A; Simeone E; de Michele I; Palmieri G; Castello G
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):45-52. PubMed ID: 15990330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas.
    Thomé SD; Loprinzi CL; Heldebrant MP
    Mayo Clin Proc; 2002 Sep; 77(9):913-7. PubMed ID: 12233924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes and prognostic factors of high-risk malignant melanoma patients after surgery and adjuvant high-dose interferon treatment: a single-center experience.
    Akman T; Oztop I; Unek IT; Koca D; Unal OU; Salman T; Yavuzsen T; Yilmaz AU; Somali I; Demir N; Ellidokuz H
    Chemotherapy; 2014; 60(4):228-38. PubMed ID: 25870939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for cutaneous melanoma.
    Treisman J; Garlie N
    Clin Plast Surg; 2010 Jan; 37(1):127-46. PubMed ID: 19914464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous head and neck melanoma: the old and the new.
    Rigual NR; Popat SR; Jayaprakash V; Jaggernauth W; Wong M
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):403-12. PubMed ID: 18366288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.
    Pirard D; Heenen M; Melot C; Vereecken P
    Dermatology; 2004; 208(1):43-8. PubMed ID: 14730236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.